Somewhat Favorable Media Coverage Somewhat Unlikely to Affect OpGen (OPGN) Stock Price

Media coverage about OpGen (NASDAQ:OPGN) has trended somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. OpGen earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 45.7356852225935 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of OpGen (OPGN) opened at $0.17 on Tuesday. The company has a current ratio of 1.23, a quick ratio of 1.13 and a debt-to-equity ratio of 0.03. OpGen has a fifty-two week low of $0.16 and a fifty-two week high of $1.85. The stock has a market capitalization of $9.46, a PE ratio of -0.27 and a beta of 0.96.

A number of analysts have recently issued reports on the company. Zacks Investment Research upgraded OpGen from a “hold” rating to a “buy” rating and set a $0.25 target price for the company in a report on Tuesday, November 14th. HC Wainwright reiterated a “buy” rating and set a $1.00 target price on shares of OpGen in a report on Tuesday, October 24th.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect OpGen (OPGN) Stock Price” was published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at

About OpGen

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Insider Buying and Selling by Quarter for OpGen (NASDAQ:OPGN)

What are top analysts saying about OpGen? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for OpGen and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit